

REMARKS

Amendments

The new claims are substantially the same as those canceled, except that new claim 17 now recites SEQ ID NO:9 and provides the functional limitations disclosed in the specification; see p.11, line 27 - p.14, line 13. Subsequent claims have been divided by dependencies. These amendments introduce no new matter.

35USC112, first paragraph (written description)

The claims are in compliance with the enablement requirement of 35USC112.


Claim 17 requires a protein comprising residues 287-334 of SEQ ID NO:2 (SEQ ID NO:9). This sequence defines a novel third cIAP "BIR domain", which sequence is separately disclosed as SEQ ID NO:9. The claims expressly require that the recited domain provides a protein:protein interaction domain which binds a TRAF1 or TRAF2. The Specification teaches that the cIAP BIR domains represent novel protein-protein interaction domains and how multiple BIR domains can be mixed-and-matched in functional recombinant chimeras (e.g. Specification, p.12, lines 10-14). The Specification shows in experimental detail how to screen for interactions of such BIR domain containing proteins with proteins like TRAF1 and TRAF2 (e.g. Specification, p.11, line 27 - p.14, line 13). Accordingly, the Specification conveys both possession and use of proteins comprising the specifically recited cIAP BIR domain.

Discerning and even practicing the invention does not require invoking Holy Grails or legendary knights of King Arthur; the invention does not relate to some hypothetical 3rd cIAP protein, nor does the invention require determining three dimensional molecular structures of anything. The present invention and relevant issues are much more mundane. A novel protein interaction domain is disclosed. The ability to recombine this domain into functional chimeric proteins is disclosed. And the claims are properly limited to a protein specifically comprising the novel interaction domain.

The Examiner is invited to call the undersigned if he would like to amend the claims to clarify the foregoing or seeks further clarification of the claim language.

We petition for and authorize charging our Deposit Account No.19-0750 all necessary extensions of time. The Commissioner is authorized to charge any fees or credit any overcharges relating to this communication to our Dep. Acct. No.19-0750 (order T95-005-2).

Respectfully submitted,
SCIENCE & TECHNOLOGY LAW GROUP



Richard Aron Osman, J.D., Ph.D., Reg. No. 36,627
Tel: (650) 343-4341; Fax: (650)343-4342

"To Help Our Customers Get Patents"
Mission Statement, USPTO External Customer Services Guide